May 18, 2025, 00:34

ERC for Non-European Researchers

The ERC for Non-European Researchers offers a powerful opportunity for global talent to lead frontier research at institutions in the EU or Horizon Europe-associated countries. The European Research Council (ERC) funds top-tier investigators of any nationality who propose pioneering projects in any field, including life sciences, social sciences, and interdisciplinary research. Its grants are internationally recognized for their prestige and support of scientific excellence.

Eligibility Criteria:

Open to researchers of any nationality and age
Must carry out the research in an EU Member State or Associated Country
Host institution must be established in an EU or associated country
Researchers relocating to Europe can apply for enhanced funding
Applicants must dedicate a minimum of:
- 50% of their time to the ERC project for Starting Grants
- 40% for Consolidator Grants
- 30% for Advanced Grants
- And must spend at least 50% of total working time within the EU or associated country
In Synergy Grants, one PI may be hosted full-time outside the EU or associated countries

Funding Details:

Up to 2.5 million EUR for Starting Grants (vs. 1.5 million EUR for Europe-based applicants)
Up to 3 million EUR for Consolidator Grants (vs. 2 million EUR)
Up to 3.5 million EUR for Advanced Grants (vs. 2.5 million EUR)
Additional top-up funding supports relocation costs, major equipment, and large-scale work
ERC grants cover 100% of eligible direct costs plus 25% toward indirect costs

Deadline:

Varies by grant type (Starting, Consolidator, Advanced, Synergy)
Calls typically open once per year and run for 3 months
Submit via the EU Funding & Tenders Portal

Where to Apply / Learn More:

ERC Website – Non-European Researchers
EU Funding & Tenders Portal
ERC Podcast – Soundcareers with the ERC: Lydia Lynch
Euraxess Jobs Portal – for research position openings on ERC projects
Contact your National Contact Point for personalized support

cancer erc grants erc non-european researchers European Research Council frontier research europe global scientific talent international research funding moving to europe for research OncoDaily Oncology

DESTINY-Breast06 Trial Updates at ESMO Breast 2025 Confirms T-DXd Efficacy in HER2-Low and Ultralow Metastatic Breast Cancer

FDA Approves Belzutifan (Welireg) for Advanced Pheochromocytoma and Paraganglioma: Results of LITESPARK-015 Trial

New World Cancer Declaration 2025–2035 by UICC

Agenus Bets Big on Botensilimab

Carlos Rodriguez-Galindo: Childhood cancer has long been overlooked in global strategies - It is time to change that